This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ProSomnus Temettü

Temettü kriter kontrolleri 0/6

ProSomnus does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.72
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Positive Sentiment Still Eludes ProSomnus, Inc. (NASDAQ:OSA) Following 35% Share Price Slump

Feb 22

ProSomnus, Inc.'s (NASDAQ:OSA) Shares Leap 60% Yet They're Still Not Telling The Full Story

Dec 20

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if OSAP.Q's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if OSAP.Q's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

ProSomnus Piyasaya Karşı Temettü Getirisi

OSAP.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OSAP.Q)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (OSAP.Q) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate OSAP.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate OSAP.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate OSAP.Q's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as OSAP.Q has not reported any payouts.

This company listing is no longer active

ProSomnus Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

ProSomnus, Inc. Emerged from Bankruptcy

ProSomnus, Inc. Emerged from Bankruptcy

Second Amended Joint Reorganization Plan Approved for ProSomnus, Inc.

First Amended Disclosure Statement Approved for ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

First Amended Reorganization Plan & Disclosure Statement Filed by ProSomnus, Inc.

ProSomnus, Inc. announced delayed 10-Q filing

Prosomnus Contributes Two Scientific Abstracts Accepted for Presentation At the 2024 American Academy of Dental Sleep Medicine Annual Meeting

Motion for Joint Administration Filed by ProSomnus, Inc.

ProSomnus, Inc. Filed for Bankruptcy

Nasdaq Files A Form 25 with the SEC to Remove ProSomnus, Inc.'s Securities from Listing

New major risk - Share price stability

ProSomnus, Inc.(OTCPK:OSAP) dropped from NASDAQ Composite Index

New major risk - Market cap size

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ProSomnus Provides Non-Compliance Update

Prosomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

Positive Sentiment Still Eludes ProSomnus, Inc. (NASDAQ:OSA) Following 35% Share Price Slump

ProSomnus, Inc. to Report Q4, 2023 Results on Mar 18, 2024

ProSomnus, Inc. Submits a Hearing Request to the Panel on February 16, 2024 to Appeal the Staff's Delisting Determination

ProSomnus, Inc. Severe Indication 510(K) Submission Accepts for Review by the Fda

ProSomnus, Inc.'s (NASDAQ:OSA) Shares Leap 60% Yet They're Still Not Telling The Full Story

Consensus EPS estimates fall by 36%

New major risk - Financial position

Third quarter 2023 earnings: EPS misses analyst expectations

New major risk - Market cap size

ProSomnus Receives A Notification Letter from Listing Qualifications Department of Nasdaq

ProSomnus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Share price stability

ProSomnus, Inc. announced that it expects to receive $25 million in funding from Spring Mountain Capital, LP and other investors

Prosomnus, Inc. Announces Updated Clinical Trial Data

ProSomnus Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5450(b)(2)(A)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProSomnus, Inc. Announces Cessation of Mark Murphy as Executive Officer

ProSomnus, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.43 loss per share (vs US$0.12 loss in 1Q 2022)

Full year 2022 earnings released: US$0.71 loss per share (vs US$0.24 loss in FY 2021)

ProSomnus, Inc. Provides Revenue Guidance for the Year Ended December 31, 2022

ProSomnus, Inc. Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

ProSomnus, Inc. Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO(TM) in Treating Severe Obstructive Sleep Apnea

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin